UK Health Committee issues 3-year report on NICE (UK National Institute for Clinical Excellence):
This article was originally published in Clinica
As Clinica went to press, the UK House of Commons Select Committee for Health published its report of the first three years of operation of the National Institute for Clinical Excellence (NICE). The institute's chairman, Professor Sir Michael Rawlins, welcomed the assessment as a thorough, important and positive exercise. "There is much to consider", he said, regarding proposals to reform NICE's approach to what is a "challenging remit". NICE is to discuss the report at its annual general meeting, on July 17; a more detailed response will be agreed at the institute's board meeting, in September.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.